Endocrine Metabolic & Immune Disorders-Drug Targets JCR impact factor overview
Automatically generated from the journal record shown on this page.
Clarivate JCR impact factor overview
Endocrine Metabolic & Immune Disorders-Drug Targets is listed in this directory with bibliometric information for 2025. It is published by BENTHAM SCIENCE PUBL LTD. The database records a Journal Impact Factor of 2.000, presented as a Clarivate Journal Citation Reports (JCR)-based metric. Its listed JCR Impact Factor quartile is Q3.
Ranking and quartile
The recorded JCR Impact Factor category rank is 232 out of 352 journals in its listed category. A Q3 designation describes the journal’s position within its subject category; it should not be used as a direct measure of the quality of an individual article.
Citation profile
The record contains 2,539 total citations, 148 total articles, 233 citable items. The five-year Impact Factor is 2.000, which is equal to the listed standard Journal Impact Factor. These values use different citation windows and should be interpreted together rather than as a direct trend. The Journal Impact Factor without journal self-citations is recorded as 1.900. The Journal Citation Indicator is listed as 0.450.
Citation half-life
The cited half-life is recorded as 4.1 years, describing the median age of articles cited in the reporting year. The citing half-life is 6.8 years, reflecting the median age of references used by the journal’s articles.
Journal identifiers and verification
Endocrine Metabolic & Immune Disorders-Drug Targets is identified in this record by print ISSN 1871-5303 and electronic ISSN 2212-3873. Use the ISSN when checking library catalogues, publisher records, indexing databases, or the official Clarivate Journal Citation Reports entry.
Complete journal information
All values below come directly from the database record.
| Journal name | Endocrine Metabolic & Immune Disorders-Drug Targets |
|---|---|
| Abbreviated journal | ENDOCR METAB IMMUNE |
| Publisher | BENTHAM SCIENCE PUBL LTD |
| Metric year | 2025 |
| Overall rank | 8,303 |
| ISSN | 1871-5303 |
| eISSN | 2212-3873 |
| Total cites | 2,539 |
| Total articles | 148 |
| Citable items | 233 |
| Cited half-life | 4.1 years |
| Citing half-life | 6.8 years |
| JCR-based Journal Impact Factor | 2.000 |
| 5-Year Impact Factor | 2.000 |
| Impact Factor without journal self-cites | 1.900 |
| Journal Citation Indicator | 0.450 |
| JCR Impact Factor quartile | Q3 |
| JCR category rank | 232/352 |
| Database record updated |
Frequently asked questions
What is the 2025 JCR-based Journal Impact Factor of Endocrine Metabolic & Immune Disorders-Drug Targets?
The Journal Impact Factor recorded in this directory as a Clarivate Journal Citation Reports (JCR)-based value for Endocrine Metabolic & Immune Disorders-Drug Targets is 2.000 for the 2025 metric year.
What quartile is Endocrine Metabolic & Immune Disorders-Drug Targets?
Endocrine Metabolic & Immune Disorders-Drug Targets is listed in quartile Q3. Quartiles describe a journal’s position within a subject category and should be interpreted within that field.
Who publishes Endocrine Metabolic & Immune Disorders-Drug Targets?
Endocrine Metabolic & Immune Disorders-Drug Targets is listed as being published by BENTHAM SCIENCE PUBL LTD.
Can a JCR Journal Impact Factor be used to judge an individual article?
No. The Journal Impact Factor is a journal-level citation measure reported in Clarivate Journal Citation Reports. It does not measure the quality, reliability or influence of every individual article published by that journal.
Related journal profiles
Additional records from the same publisher or with a similar listed JCR Impact Factor.